Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Seeking Alpha
Aishwarya Sitharam - Lead of Investor Relations Mannam Venkatanarasimham - CFO & Member of the Management Council Erez Israeli - CEO & Member of the Management Council Conference Call Participants Neha Manpuria - BofA Securities, Research Division Damayanti Kerai - HSBC Global Investment Research Bino Pathiparampil - Elara Securities (India) Private Limited, Research Division Abdulkader Puranwala - ICICI Securities Limited, Research Division Kunal Dhamesha - Macquarie Research Madhav Marda - Fidelity Investments Shyam Srinivasan - Goldman Sachs Group, Inc., Research Division Tushar Manudhane - Motilal Oswal Securities Limited, Research Division Vivek Agrawal - Citigroup Inc., Research Division Kunal Lakhan - CLSA Limited, Research Division Shashank Krishnakumar - Emkay Global Financial Services Ltd., Research Division Surya Patra - PhillipCapital (India) Pvt. Ltd., Research Division Foram Parekh - BOB Capital Markets Limited, Research Division Presen
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]Seeking Alpha
- Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "buy (b-)" rating to a "hold (c+)" rating.MarketBeat
- Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.Business Wire
- Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid MalignanciesBusiness Wire
RDY
Earnings
- 1/22/26 - Beat
RDY
Sec Filings
- 1/22/26 - Form 6-K
- 1/21/26 - Form 6-K
- 1/21/26 - Form 6-K
- RDY's page on the SEC website